BK polyomavirus in the urine for follow-up of kidney transplant recipients.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 27 03 2018
revised: 22 07 2018
accepted: 24 07 2018
pubmed: 5 8 2018
medline: 26 4 2019
entrez: 5 8 2018
Statut: ppublish

Résumé

After kidney transplantation, human BK polyomavirus (BKPyV) can induce a progressive disease, in three stages: viruria, viraemia, and then nephropathy after a few months of viral replication. Therapeutic intervention is recommended when BKPyV is detected in the plasma. The objective of our study was to assess urinary BKPyV nucleic acid test as a predictor for developing viraemia. We first defined a viruria threshold based on 393 time-matched urine and plasma samples collected after kidney transplantation; to validate this threshold, we followed-up a cohort of 236 kidney transplant patients. A BKPyV viruria threshold of 6.71 log Sustained BKPyV viruria is a reliable, early marker of patients at high risk of developing BKPyV viraemia. This marker should alert the clinician early, and thus allow timely therapeutic intervention.

Identifiants

pubmed: 30076973
pii: S1198-743X(18)30545-7
doi: 10.1016/j.cmi.2018.07.027
pii:
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112.e1-112.e5

Informations de copyright

Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

E Brochot (E)

Department of Virology, Amiens University Medical Centre, Amiens, France; AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France. Electronic address: etienne.brochot@u-picardie.fr.

V Descamps (V)

Department of Virology, Amiens University Medical Centre, Amiens, France; AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France.

L Handala (L)

Department of Virology, Amiens University Medical Centre, Amiens, France; AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France.

J Faucher (J)

Department of Nephrology, Amiens University Medical Centre, Amiens, France.

G Choukroun (G)

Department of Nephrology, Amiens University Medical Centre, Amiens, France.

F Helle (F)

AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France.

S Castelain (S)

Department of Virology, Amiens University Medical Centre, Amiens, France; AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France.

C François (C)

Department of Virology, Amiens University Medical Centre, Amiens, France; AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France.

G Duverlie (G)

Department of Virology, Amiens University Medical Centre, Amiens, France; AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France.

A Touzé (A)

UMR INRA 1282 ISP, Biologie des Infections à Polyomavirus, Faculté des Sciences Pharmaceutiques, Université de Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH